Business
Presentation at H.C. Wainwright Global Conference
Presentation at H.C. Wainwright Global Conference.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n 1 September 2022\n \n \n Hemogenyx Pharmaceuticals plc \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n \n Presentation at H.C. Wainwright Global Investment Conference\n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the\n \n H.C. Wainwright 24th Annual Global Investment Conference to be held on September 12-14, 2022, in New York City\n \n . The Company will be featured as a presenting company.\n The conference will be hosted both in person as well as virtually under a hybrid model.\n \n \n \n As part of the Company's presentation, Dr Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business, product candidates and their progression toward clinical trials.\n \n \n \n \n The conference will feature corporate presentations, panels, and one-on-one investor meetings. Dr Sandler's presentation will be accessible using a webcast link for registered conference participants.\n \n \n \n Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: \n \n \"Our presentation at the H.C. Wainwright\n \n 24th Annual Global Investment Conference\n \n provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases.\"\n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n \n \n \n \n https://hemogenyx.com\n \n \n \n \n \n \n \n Dr Vladislav Sandler, Chief Executive Officer & Co-Founder\n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n Peter Redmond, Director\n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n SP Angel Corporate Finance LLP\n \n \n \n \n \n Tel: +44 (0)20 3470 0470\n \n \n \n \n \n \n Matthew Johnson, Vadim Alexandre, Adam Cowl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Peterhouse Capital Limited\...